WO2000027224A1 - Health-promoting foods - Google Patents

Health-promoting foods Download PDF

Info

Publication number
WO2000027224A1
WO2000027224A1 PCT/JP1999/006238 JP9906238W WO0027224A1 WO 2000027224 A1 WO2000027224 A1 WO 2000027224A1 JP 9906238 W JP9906238 W JP 9906238W WO 0027224 A1 WO0027224 A1 WO 0027224A1
Authority
WO
WIPO (PCT)
Prior art keywords
genus
health
ebine
angelica
plant belonging
Prior art date
Application number
PCT/JP1999/006238
Other languages
French (fr)
Japanese (ja)
Inventor
Manabu Nomura
Original Assignee
Manabu Nomura
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Manabu Nomura filed Critical Manabu Nomura
Priority to AU11765/00A priority Critical patent/AU1176500A/en
Publication of WO2000027224A1 publication Critical patent/WO2000027224A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • A61K36/232—Angelica
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/898—Orchidaceae (Orchid family)

Definitions

  • the present invention relates to a health supplement that utilizes the excellent disease-ameliorating effect and health-retaining function of the genus Umbelliferae of the Umbelliferae family.
  • euphoria As representatives of the cedars of the genus Apiaceae, commonly referred to as euphoria, euphorbia, inu genus, and hyuga touki (hereafter, euphoria) have been known.
  • Hyuga-Tuki the disease ameliorating effect and the health maintenance function of Hyuugatsuki have not been verified so far.
  • the present inventor has focused on the pharmacological activity of Inu-Toki, and as a result of diligent research on the plant of the same genus, Hyuga-Tuki, various types of Hyuga-Tuki that are superior to Inu-Tuki are shown. It was found to have pharmacological effects and was found to be useful as a dietary supplement.
  • the present inventor has found that by adding the ebine to the eucalyptus, the amelioration of the illness peculiar to the eucalyptus and the further improvement of health can be achieved. It has been found that a holding function can be obtained.
  • the present invention is based on such findings, and has an object to provide a natural plant-derived safe dietary supplement having an excellent disease ameliorating effect and a health maintaining function. Disclosure of the invention
  • the health supplement of the present invention which has achieved the above object, is characterized in that a processed product of the genus Hydrangea sp.
  • the health supplement of the present invention is characterized in that a mixture of a processed product of a plant belonging to the genus Apiaceae and a processed product of a plant belonging to the genus Ebine belongs to the active ingredient.
  • typical examples of plants belonging to the genus Shishido of the Umbelliferae family include Hyugata (An gelicaacutiloba), Inuuki (An gelicashicokiana), and Hyugata (Angelicatenuisecta), which is one of the strains of the genus Azenica (An gelicatenuisecta). Ki (A. furcijugakitag.).
  • Hyugatuki Ange 1 icafurcijuga K itagawa
  • Umb elliferae genus Apiaceae
  • Ansi 1 L.
  • Hyugatoki has excellent pharmacological action itself as compared with Toukijinuki, and can be used as a health supplement food useful for various diseases and health maintenance.
  • s-GOT serum transamylase
  • s-GOT serum transamylase
  • Jebine type Jebine (C. discolor), Kiebine (C. sieboldii), Kirishima ebine (C. aristu 1 ifera), Amamiebine (C. amamiana), and Nyoebine (C. izu-insularis) tricarinata), C. tokunoshimaensis, C. arisanensis, C. graciliflora, C. p1 antaginea or C. p 1 antaginea or C. ), Togaribaebine (C. caudatilabella).
  • Tin flea vine type C. 1 iukiuen sis
  • Tamazakiebine C. densiflora
  • Bulkura C. pu 1 chra
  • Taganelan type Taganelan (C. bungoana), Whiteana (C. whiiteana).
  • Sakurajima shrimp type Sakurajima shrimp (C.ob1ancceo1ata, mannii (C.mannii)).
  • Kisoebine type Kisoebine (C. schlecchtteri), Alpina (C. a1pina).
  • Hiro no nokaran type Hiro no nokaran (C. jap0nica).
  • Natsuebine type Natsuebine (C. ref f1exa).
  • Turran types Turran (C. furcata), Onagae Bine (C. longicalcarata), Okinadjebine (C. okinawaensis), Trout sword (C. ma suca), Mag sword (C. madagascariensis), Natalensis (C. natalensis).
  • Toxalan type Toxalan (C. venusta), white toxalan (C. longipes), biloba (C. bi1oba).
  • the processed product is a dry powder, a small piece, a frozen powder, a pressed product, a pressed product of a corn or ebine. Juices, extracts, extracts, etc. What is processed by such means widely means. It also includes granulation using powder, granules, capsules, and the like.
  • Fig. 1 is a table showing the inhibitory effect of the processed product and its components on D-Ga1N / LPS-induced hepatic injury in mice
  • Fig. 2 is a first-generation cultured rat liver using a compound containing a hyugatouki
  • FIG. 3 is a table showing the effect of the components of Hyuuga-touki on D-Ga1N-induced hepatotoxicity in cells.
  • FIG. 3 shows the nitric oxide production inhibitory activity of the compounds containing Hyuga-gatouki on the activation of intraperitoneal macula phage in mice.
  • Fig. 1 is a table showing the inhibitory effect of the processed product and its components on D-Ga1N / LPS-induced hepatic injury in mice
  • Fig. 2 is a first-generation cultured rat liver using a compound containing a hyugatouki.
  • FIG. 3 is a table showing the effect of the components of Hyuuga-touk
  • Fig. 4 is a table showing the health supplement function of Hyugatuki alone extract and a mixed extract of Hyugatuki and Ebine
  • Fig. 5 is a chart of Ginseng alcohol extract and Isoepoxybuterixin.
  • a graph showing the inhibitory effect of skin tumor on CD-1 mice. (A) shows the number of mice with tumors, and (mouth) shows the number of tumors per mouse. Show. BEST MODE FOR CARRYING OUT THE INVENTION
  • Hyugatuki which is an active ingredient of the dietary supplement according to the present invention, uses cultivated seeds, wild flowers, roots, stems, leaves, branches, and the like. Usually, it is used as a solid, such as a powder, but it can also be used as a liquid, such as an extract or pressed juice. Additives, excipients, etc. may be added to form granules, tablets, capsules and the like. Sweetening agents, such as stevia, can be added in small amounts to facilitate ingestion. In addition, vitamins commonly used in health supplements may be added.
  • the plant When used as a solid, the plant is freeze-dried or air-dried to powder.
  • the powdered product may be formed into granules, granules, pellets and the like.
  • the plant may be fragmented and dried without powdering, and used as it is. Further, a powder can be obtained by distilling a liquid component from the extract or the squeezed juice.
  • extraction or squeezing is usually used.
  • water or alcohol is used as an extraction solvent. It is common to use a mixed solution of water and alcohol, and its concentration is 10 to 100%, preferably 40 to 80% .
  • alcohol It is desirable to adjust the concentration of the aqueous solution to 25% or less.
  • the mud adhering to the rhizome is dropped and the whole plant is washed with water. Next, it is roughly cut with a cutter, mixer, etc., and squeezed with a press. Compression pressure of the press is 5 0 0-5 may be set to approximately 0 0 0 kg Z cm 2.
  • the squeezed juice can be used as is, or purified or diluted.
  • first fraction 6.6 g (0.17%), second fraction 17.7g (0.49%), third fraction 25.0 g (0.69%), respectively.
  • the water-eluting part and the first fraction were primary metabolites such as saccharides and amino acids based on thin layer chromatography studies.Therefore, the second fraction was subjected to normal-phase and reverse-phase silica gel chromatography.
  • D-galactosamine D-Ga1N 350 mg / kg and lipopolysaccharide (LPS) 10 ⁇ g / kg intraperitoneally using 25-27 g ddy female mice Injection induced liver damage.
  • LPS lipopolysaccharide
  • Each test sample was given 1 hour prior to D-GaI N / L PS injection. Blood collection was performed 10 hours after D-Ga1N / L PS injection. Each value indicates the average value by S.E.M (p ⁇ 0.05, p ⁇ 0.01).
  • FIG. 1 shows the dose and the serum transaminase activity value (s-GPT, s-GOT) of each sample.
  • Test Example 2 Protective action against D—Ga1N-induced cytotoxicity
  • the hepatoprotective effect of the extract of Hyugatuki was determined using primary cultured hepatocytes using 3 — (4,5-dimethylthiazol-2-yl) — 2-, 5-diphenyltetrazolazole bromide (MTT) colorimetric assay. It was measured by. Hepatocytes were isolated from male diaster rats (130-160 g) by the collagen spray method.
  • Inhibition rate (%) ⁇ (Sample OD—Control group OD) ⁇ (Normal group ⁇ . D—Control group OD) ⁇ Test example 3 (Anti-inflammatory pharmacological activity)
  • mice Male ddy mice (body weight about 30 g) were euthanized by cervical dislocation, and 6-7 ml of buffered saline (PBS) was injected into the abdominal cavity and gently massaged. The obtained peritoneal exudate was washed with PBS and then with RPMI 11640 (containing 10% fetal calf serum, 100 units / ml penicillin, 100 gZml and streptomycin) medium. 5 ⁇ 10 5 cells / 100 ⁇ l of cells were added per well to a 96-well flat bottom microplate, and the cells were cultured at 37 ° C. in a 5% carbon dioxide gas / 95% air atmosphere for 1 hour.
  • PBS buffered saline
  • the suspended cells are washed with PBS, and 200 ⁇ l of lipopolysaccharide (from Sigma, derived from Salmonella enteridisis) containing l O / xg / ml and a test substance is added to the above culture solution, and then added to the culture medium. Cultured for hours. Add 100 g of culture supernatant to a grease reagent (1% (Luphanilamide and 0.1% N-1-naphthylethylenediamine dihydrochloride dissolved in 2.5% phosphoric acid) were added, and the mixture was allowed to stand at room temperature for 10 minutes. The absorbance was measured using a microplate reader (measurement wavelength: 562 nm, control wavelength: 630 nm). The amount of NO— accumulated in the culture broth using sodium nitrite as a standard substance was determined as the amount of NO produced.
  • phalkanol, phalkanoldiol, and disoepoxybuterixin obtained in Examples were used, and hydrocortisone was used as a control drug known to have an anti-inflammatory effect.
  • the results are shown in FIG.
  • serum transaminase activity s-GPT, s-GOT
  • s-G ⁇ ⁇ were significantly suppressed in the groups administered with the substances derived from Hyuga-touki, including pharmacaldiol.
  • MTT assay method is a cell counting method that utilizes the fact that yellow MTT changes to magenta formazan by cell dehydrogenase.
  • iso-epoxybuterixin exhibited a concentration-dependent hepatocyte protective effect.
  • falcarindiol on the contrary, showed toxicity to hepatocytes.
  • Isopteryxin was found to have a protective effect as another minor component.
  • macrophage activation was suppressed by using the amount of nitric oxide (NO), which is produced by the activation of macula phage by LPS. Since NO is that changes to NO 2 immediately oxidized, it was considered as the amount of N_ ⁇ the amount of NO 2 in the culture solution.
  • NO nitric oxide
  • isoepoxybuterixin and phalkariandiol strongly inhibited NO production at a concentration that was not cytotoxic to macrophages.
  • Anomalin (anoma1 inn), benoregapten (bergapten), cellabshanin (servashchanin), and isopterixin, a novel compound, telentacin A, also exhibited an inhibitory effect, and particularly strong activity of falcarindiol was observed.
  • pharmacandiol strongly suppresses the activation of macrophages, and is considered to have suppressed this liver injury.
  • isoepoxybuterixin not only exerts hepatoprotective action by acting on the liver side, but also suppresses D-Ga1N / IPS-induced liver damage by suppressing macrophage activation. .
  • Test Example 4 Anti-tumor pharmacological activity
  • mice Female CD-1 in experimental animals? Groups of 88-week-old mice were grouped into 20 mice. Two days before the experiment, mice with shaved hair and a hair resting period were used. All samples were dissolved in acetone and applied with 0.2 ml of micropipette to shaved skin. First, dimethylbenzenanthracene (DMBA) 200 nm 01 was applied to mouse skin as an initiator of carcinogenesis. Ten days later, 5 nmol of tetradecanol phorbol-13-acetate (TPA) was applied twice a week, and the treatment was continued for 18 weeks. The samples were applied twice a week at the same time as the TPA application and continued for 18 weeks.
  • DMBA dimethylbenzenanthracene
  • TPA tetradecanol phorbol-13-acetate
  • health supplements containing as an active ingredient a mixture of a processed product of a plant belonging to the genus Umbelliferae and a processed product of a plant belonging to the genus Ebine belong to the processed products of the ibis and ebine.
  • the composition ratio of ebine is preferably 4 to 2 with respect to 6 to 8 of eucalyptus. If the mixing ratio of ebine is high, it is highly irritating and difficult to ingest.
  • the addition of vinegar, especially black vinegar significantly enhances the function of dietary supplements. It is desirable to adjust the pH of the mixed solution to about 3 to 5 by adding vinegar from the viewpoint of improving storage stability.
  • sweeteners such as stevia may be added in small amounts to facilitate ingestion.
  • the addition of vitamins commonly used in health supplements is optional.
  • This mixed dietary supplement of eucalyptus and ebine is usually provided as a liquid beverage consisting of squeezed juice or extract. They can also be provided in granules, tablets, and capsules. Additives, excipients, etc. can be added to the squeezed juice or extract to form granules, tablets, capsules and the like.
  • the daily intake should be 10 to 30 ml Z 2 to 3 times as a normal liquid health supplement.
  • the health supplement of the present invention can be produced, for example, as follows. First of all, as the raw materials, all vegetation such as leaves, stems, flowers, and roots can be used for the ibis and ebine, but the root is particularly preferable. In both cases, the whole plant is washed with water, and cut with a cutter or mixer. Next, 2 kg of the roughly cut and dried oysters are cooked at a rate of 20 liters of water. On the other hand, 1 kg of ebine is water 10 Cook at a little rate. Pressed juice may be used, but cook over low heat until the volume is reduced to about 1/3. Usually takes 4-5 hours. After boiling, allow to cool to room temperature, filter and mix. The mixture is desirably added with 5 to 15% of black vinegar to adjust the pH to about 3 to 5. Add an appropriate amount of sweetener, such as stevia, to make it easier to drink.
  • sweetener such as stevia
  • Hyugatuki native to southern Miyazaki prefecture was used.
  • the leaves, stems, roots, and other whole plants were washed with water and roughly cut with a power cutter.
  • 2 kg of the dried and dried hyuugatsuki was boiled with 20 liters of water. Finally, they cooked on low heat until the capacity was about 1/3. The boiling time was 4 hours. After boiling, the mixture was allowed to cool to room temperature, and the solid was filtered off. About 10% of the total amount of black vinegar was added to the mixture, and the pH was adjusted to 4. A small amount of stevia was added to this as a sweetener.
  • Hyugatuki native to southern Miyazaki prefecture was used for corn, and Jebine native to southern Miyazaki prefecture was used for ebine. All leaves, stems, The whole plant, including the roots, was washed with water and roughly cut with a power cutter. 2 kg of the dried and dried hyuga touki was boiled with 20 liters of water. 1 kg of the coarsely cut Jebine was boiled with 10 liters of water. Finally, they cooked on low heat until the capacity reached about 13. The boiling time was 4 hours. After boiling, the mixture was allowed to cool to room temperature, and solids were separated by filtration and mixed. About 10% of the total amount of black vinegar was added to the mixture, and the pH was adjusted to 4. A small amount of stevia was added to this as a sweetener. Control Example 1
  • FIG. 4 qualitatively shows the disease improving function and the health maintenance function of the samples shown in Examples 1 and 2 and Control Examples 1 and 2.
  • the anticancer effects of corns include isepoxyshibuterixin, which is a new coumarin, terantacoside A, a turpentine KB, a new coumarin glycoside, turpentine I, The lactone in the coumarin skeleton is found in the ring-opened new compound telternacide ⁇ and the new lignan tetancoside m.
  • anti-cancer effects have also been recognized on ebine, which has long been known as a specific drug for uterine diseases.
  • Example of anti-hepatitis action The anti-hepatitis action as a citrus extract is known in Japanese Patent Application Laid-Open No. Hei 4-33665. It is also found in the contained falcarin diol and isoepoxybuterixin.
  • Example of anti-inflammatory action The anti-inflammatory action as a rubrum extract is also known in Japanese Patent Publication No. 5-48233, but according to the knowledge of the present inventors, it is known that the alkanol contained in rubbles contains , And also found in phthalic diols.
  • Example of anti-allergic action It is known in Japanese Patent Publication No. 5-482333 that iso-epoxybuterixin containing turkeys has anti-inflammatory and anti-allergic activity. Further, according to the findings of the present inventors, indirubin and tryptatrin contained in ebine have a strong antiallergic action, and also have an action as an antitopy, an antidandruff agent, an antibacterial agent and the like. Is recognized.
  • Example of anti-diabetic action The anti-diabetic action as a eucalyptus extract is also known in Japanese Patent Application Laid-Open No. 7-530600, but according to the knowledge of the present inventors, it is also recognized in falcarindiol contained in eucalyptus. .
  • vasodilatory action as an extract of eucalyptus is disclosed in Japanese Patent Application Laid-Open No. 4-33665, and the isoepoxybuterixin contained in eucalyptus is disclosed in Japanese Patent Application Laid-open No. Hei 7-53560.
  • strong vasodilatory action is also observed for Ebine.
  • Example of anti-hyperlipidemic action The anti-lipidemic action as a turkey extract is known from Japanese Patent Publication No. 4-33365. Industrial availability
  • the hyugatuki of the present invention contains a large number of pharmacologically active substances and, for example, suppresses an anticancer effect and an antihepatitis effect and can be widely used as a health supplement.
  • hyugatuki is a natural plant with no side effects and can be taken for a long time with confidence.
  • a mixture comprising a squeezed juice and an extract of the corns and ebine of the present invention
  • a health supplement for example, anti-cancer, hepatitis treatment, anti-inflammatory, anti-allergy
  • It can be expected to have various uses such as diseases, diabetes, vasodilation, treatment of hyperlipidemia, prevention of arteriosclerosis, and stamina. It is especially effective as a health supplement with anti-cancer and anti-hepatitis effects with a low recurrence rate.
  • both ibis and ebine are naturally occurring plants, have no acute toxicity and can be taken safely for a long period of time. Therefore, they are suitable for daily health maintenance such as improvement of chronic diseases and lifestyle-related diseases.

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Botany (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medical Informatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Health-promoting foods containing as the active ingredient processed products of Umbelliferae Angelica furcijuga and health-promoting foods containing as the active ingredient mixtures of plants belonging to Umbelliferae Angelica and plants belonging to Orchidaceae Calanthe. For example, dried whole plants (leaves, stems, roots, etc.) of plants of Angelica and Calanthe are washed with water and roughly cut with a cutter. 2 kg of the Angelica plant pieces are boiled in 20 l of water, while 1 kg of the Calanthe plant pieces are boiled in 10 l of water. These mixtures are cooked over a low flame to reduce the volume to about 1/3. After boiling and cooling by allowing to stand to room temperature, these mixtures are filtered and combined. To the obtained mixture, 5 to 15 % of black vinegar is added to regulate the pH value to about 4 to 5. Then an appropriate amount of a sweetener is added thereto. The extract thus obtained has the potent effects of ameliorating diseases (anticancer effect, anti-inflammatory effect, etc.) of Angelica as well as the potent antibacterial effect and anti-inflammatory effect of Calanthe, thereby giving health-promoting foods which have never been obtained so far.

Description

明 細 書 健康補助食品 技術分野  Description Health supplements Technical field
本発明は、 セリ科のシシゥ ド属トウキ類のすぐれた疾病改善作用及び 健康保持機能を利用した健康補助食品に関するものである。 背景技術  TECHNICAL FIELD The present invention relates to a health supplement that utilizes the excellent disease-ameliorating effect and health-retaining function of the genus Umbelliferae of the Umbelliferae family. Background art
俗称トウキ類といわれるセリ科シシウ ド属トゥキ類の代表的なもの としては、 トウキ、 ィヌ トウキ、 ヒュウガトゥキ等 （以下 「トウキ類」 という） がこれまで知られている。  As representatives of the cedars of the genus Apiaceae, commonly referred to as euphoria, euphorbia, inu genus, and hyuga touki (hereafter, euphoria) have been known.
近年、 ィヌ トウャ (An g e l i c a s h i k o k i a n a M a k i n o ) を有効成分とする肝機能改善用あるいは抗高脂血症用医薬組 成物が知られている （特公平 4— 3 3 6 5号）。 またィヌ トゥキ含有化学 物質と しては、 数種のクマリンと二種のステロールが知られている。 ク マリン系化合物のひとつであるィソエポキシブテリキシンについては、 ヒ ト白血球を用いる実験において、 抗アレルギー、 抗炎症作用があるこ とが知られている （特公平 5— 4 8 2 3 3号公報）。  In recent years, a pharmaceutical composition for liver function improvement or antihyperlipidemia containing dog tow (AngelisashikanakiMakino) as an active ingredient has been known (Japanese Patent Publication No. 4-33665). Also, several kinds of coumarins and two kinds of sterols are known as chemical substances containing inutuki. Isoepoxybuterixin, one of the coumarin compounds, is known to have anti-allergic and anti-inflammatory effects in experiments using human leukocytes (Japanese Patent Publication No. 5-482833). Gazette).
—方、 本発明者は、 ラン科のェビネ属に属する植物 （以下 「ェビネ類」 という） が強い抗菌作用や血流改善作用を有し、 育毛 ·養毛剤と して有 用であることを明らかにしている（特開平 5— 2 9 4 8 1 3号公報）。  On the other hand, the present inventors have found that a plant belonging to the genus Ebine of the family Orchidaceae (hereinafter referred to as “ebine”) has a strong antibacterial action and a blood flow improving action, and is useful as a hair restoration and hair restoration agent. (Japanese Unexamined Patent Publication No. Hei 5-292948).
しかしながら、 トウキ類の中でも、 ヒュウガトゥキの疾病改善作用や 健康保持機能は、 これまでほとんど検証されていなかった。本発明者は、 ィヌ トウキの薬理活性に着目 して、 同属の植物であるヒュウガトゥキに ついて鋭意研究した結果、 ヒュウガトゥキにはィヌ トゥキに勝る種々の 薬理作用があることが分かり、 健康補助食品と して有用であることを見 出した。 However, among the ibis species, the disease ameliorating effect and the health maintenance function of Hyuugatsuki have not been verified so far. The present inventor has focused on the pharmacological activity of Inu-Toki, and as a result of diligent research on the plant of the same genus, Hyuga-Tuki, various types of Hyuga-Tuki that are superior to Inu-Tuki are shown. It was found to have pharmacological effects and was found to be useful as a dietary supplement.
また トゥキ類とェビネ類の混合物は、 これまで全く知られていなかつ たが、 本発明者は、 トウキ類にェビネ類を添加することにより、 トウキ 類固有の疾病改善作用の強化と、 一層の健康保持機能とが得られること を見いだした。  Further, although a mixture of the ibis and the ebine have not been known at all, the present inventor has found that by adding the ebine to the eucalyptus, the amelioration of the illness peculiar to the eucalyptus and the further improvement of health can be achieved. It has been found that a holding function can be obtained.
本発明は、 かかる知見に基づく もので、 疾病改善作用と健康保持機能 にすぐれた天然植物由来の安全な健康補助食品を提供することを目的と している。 発明の開示  The present invention is based on such findings, and has an object to provide a natural plant-derived safe dietary supplement having an excellent disease ameliorating effect and a health maintaining function. Disclosure of the invention
前記目的を達成した本発明の健康補助食品は、 セリ科シシゥ ド属ヒュ ゥガトウキの加工物を有効成分とすることを特徴と している。  The health supplement of the present invention, which has achieved the above object, is characterized in that a processed product of the genus Hydrangea sp.
また本発明の健康補助食品は、 セリ科シシゥ ド属に属する植物の加工 物とラン科ェビネ属に属する植物の加工物との混合物を有効成分とする ことを特徴としている。  Further, the health supplement of the present invention is characterized in that a mixture of a processed product of a plant belonging to the genus Apiaceae and a processed product of a plant belonging to the genus Ebine belongs to the active ingredient.
本発明において、 セリ科のシシゥ ド属に属する植物の代表的なものと して、 トウキ （An g e l i c a a c u t i l o b a ) 、 ィヌ トウキ (An g e l i c a s h i c o k i a n a ) 、 及びカヮゼンゴ (An g e l i c a t e n u i s e c t a ) の系統の一種であるヒュウガト ゥキ （A. f u r c i j u g a k i t a g . ) などを挙げることがで さる。  In the present invention, typical examples of plants belonging to the genus Shishido of the Umbelliferae family include Hyugata (An gelicaacutiloba), Inuuki (An gelicashicokiana), and Hyugata (Angelicatenuisecta), which is one of the strains of the genus Azenica (An gelicatenuisecta). Ki (A. furcijugakitag.).
このうちヒュウガトゥキ （An g e 1 i c a f u r c i j u g a K i t a g a w a ) は、 セリ科-植物 （Umb e l l i f e r a e ) のシ シウ ド属 （An g e 1 i c a L. ) に属する植物であり、 宮崎県から 大分県の南部に分布、 特に丘陵や山地のやや乾いた草地に自生する多年 草で、 以前はィヌ トウキと誤認されていたが、 1 9 7 1年北川政夫が新 種であると発表、 その後の栽培における観察実験による比較で、 異なる 種であることが証明されている。 （宫崎産業経営大学研究紀要第 5卷第 1号/ 1 9 9 3年 1月） （宮崎県地方史研究紀要第 1 8輯ノ宮崎県立図 書館 Z平成 4年 3月） Among them, Hyugatuki (Ange 1 icafurcijuga K itagawa) is a plant belonging to the genus Apiaceae (Umb elliferae) and belongs to the genus Ansi 1 (L.), distributed from Miyazaki Prefecture to the southern part of Oita Prefecture. Perennial, especially on hills and mountainous, somewhat dry grasslands In grass, which was previously mistaken for Inuukiuki, in 1971, Masao Kitagawa announced that it was a new species, and a comparison by observation experiments in subsequent cultivation proved to be a different species . (Takasaki University of Business and Management, Vol. 5, No. 1, January 19, 2003) (Miyazaki Prefectural Local History Bulletin, No. 18, Miyazaki Prefectural Library Z March, 1994)
本発明者の知見によると、 ヒュウガトゥキは、 それ自体トウキゃィヌ トウキに比べてすぐれた薬理作用があり、 種々の疾病や健康保持に有用 な健康補助食品として利用できる。  According to the findings of the present inventor, Hyugatoki has excellent pharmacological action itself as compared with Toukijinuki, and can be used as a health supplement food useful for various diseases and health maintenance.
例えばヒュウガトゥキの粉体、 抽出液、 圧搾汁等の含有成分には、 マ ウス皮膚発癌実験系で有意に皮膚腫瘍の減少が確認されている。 また免 疫反応を介した急性肝障害モデルにおいて、 D—ガラク トサミンと リポ ポリサッカライ ド （大腸菌由来菌体内毒素） を併用することにより誘発 される肝障害を示す血清トランスアミラーゼ （ s— GOT、 s -G P T) の上昇も、 抑制されることが見出されている。  For example, a significant decrease in skin tumors has been confirmed in mouse skin carcinogenesis experimental systems for components such as hyugatuki powder, extract, and squeezed juice. In an acute liver injury model mediated by an immune reaction, serum transamylase (s-GOT, s-GOT, s-GOT, s-GOT), which shows liver injury induced by the combined use of D-galactosamine and lipopolysaccharide (endotoxin derived from Escherichia coli). GPT) has also been found to be suppressed.
—方、 本発明において用いるラン科ェビネ属に属する植物の代表的な ものと しては、 次のものを例示できる。  On the other hand, the following can be exemplified as typical examples of plants belonging to the genus Ebine orchid used in the present invention.
( 1 ) . ジェビネ型 ： ジェビネ （C. d i s c o l o r ) 、 キエビネ (C . s i e b o l d i i ) 、 キリシマエビネ （ C . a r i s t u 1 i f e r a ) 、 アマミエビネ (C . a m a m i a n a ) 、 ニォイエビネ （C. i z u - i n s u l a r i s ) , サルメンェビネ （C. t r i c a r i n a t a ) 、 トクノシマエビネ 、 C. t o k u n o s h i m a e n s i s ) 、 ァリサンェビネ （C . a r i s a n e n s i s ) 、 ホソバナェビ ネ （C. g r a c i l i f l o r a ) 、 ヒマラヤニォイエビネ （C. p 1 a n t a g i n e a ) 、 クロロレ'ゥカ ( C . c h 1 o r o 1 e u c a ) 、 トガリバエビネ （C. c a u d a t i l a b e l l a ) 。  (1). Jebine type: Jebine (C. discolor), Kiebine (C. sieboldii), Kirishima ebine (C. aristu 1 ifera), Amamiebine (C. amamiana), and Nyoebine (C. izu-insularis) tricarinata), C. tokunoshimaensis, C. arisanensis, C. graciliflora, C. p1 antaginea or C. p 1 antaginea or C. ), Togaribaebine (C. caudatilabella).
( 2 ) . スズフリエビネ型： スズフリエビネ （ C . 1 i u k i u e n s i s ) , タマザキエビネ （C. d e n s i f l o r a ) 、 ブルクラ （C. p u 1 c h r a ) 。 (2). Tin flea vine type: C. 1 iukiuen sis), Tamazakiebine (C. densiflora), Bulkura (C. pu 1 chra).
( 3 ) . タガネラン型 ： タガネラン （C. b u n g o a n a ) 、 ホヮ ィテアナ ( C . w h i t e a n a ) 。  (3). Taganelan type: Taganelan (C. bungoana), Whiteana (C. whiiteana).
( 4 ) . サクラジマエビネ型： サクラジマエビネ （ C . o b 1 a n c e o 1 a t a 、 マンニ ( C . ma n n i ) 。  (4). Sakurajima shrimp type: Sakurajima shrimp (C.ob1ancceo1ata, mannii (C.mannii)).
( 5) . キソェビネ型： キソェビネ （C. s c h l e c h t e r i ) 、 アルピナ （C. a 1 p i n a ) 。  (5). Kisoebine type: Kisoebine (C. schlecchtteri), Alpina (C. a1pina).
( 6 ) . キンセイラン型 ： キンセイラン （C. n i p p o n i c a ) 。  (6). Kinseiran type: Kinseiran (C. nippponica).
( 7 ) . ヒロノヽノカラン型： ヒロ ノヽノカラン （C. j a p 0 n i c a ) 。  (7). Hiro no nokaran type: Hiro no nokaran (C. jap0nica).
( 8 ) . アサヒェビネ型 ： アサヒェビネ （ C . h a t t o r i i ) 。 (8). Asahybine type: Asahybine (C.hattorii).
( 9 ) . ナツエビネ型： ナツエビネ （ C . r e f 1 e x a ) 。 (9). Natsuebine type: Natsuebine (C. ref f1exa).
( 1 0) . ツルラン型： ツルラン （C. f u r c a t a ) 、 ォナガエ ビネ （C. l o n g i c a l c a r a t a ) 、 ォキナヮェビネ （ C . o k i n a w a e n s i s ) 、 マス刀 ( C . ma s u c a ) 、 マグ刀スカ リ エンシス （C. m a d a g a s c a r i e n s i s ) 、 ナタ レンシス ( C . n a t a l e n s i s ) 。  Turran types: Turran (C. furcata), Onagae Bine (C. longicalcarata), Okinadjebine (C. okinawaensis), Trout sword (C. ma suca), Mag sword (C. madagascariensis), Natalensis (C. natalensis).
( 1 1 ) . トクサラン型 ： トクサラン （C. v e n u s t a ) 、 シロ トクサラン （C. l o n g i p e s ) 、 ビロバ (C . b i 1 o b a ) 。  (11). Toxalan type: Toxalan (C. venusta), white toxalan (C. longipes), biloba (C. bi1oba).
( 1 2) . ぺステイタ型 ： べステイタ （C. v e s t i t a ) 、 ロゼ ァ （C. r o s e a ) 、 エルメ リ （C. e l m e r i ) 、 ノレべンス （ C . r u b e n sリ 、 カーシォクロッサ ( C . c a r d i o g 1 o s s a ) 。 特にジェビネ、 キエビネ、 ォキナヮェビネなどが、 本発明の健康補助 食品として適している。 - 本発明において、 加工物とは、 トウキ類またはェビネ類の乾燥粉末、 細片、 凍結粉末、 圧搾物、 圧搾汁、 抽出物、 抽出液など、 天然物を何ら かの手段で加工したものを広く意味する。 また粉末を用いた造粒、顆粒、 カプセル等も含まれる。 図面の簡単な説明 (1 2). ぺ Statator type: Vesita (C. vestita), Rosea (C. rosea), Ermeli (C. elmeri), Norebens (C. rubens re, Casio crossa (C. cardiog 1 ossa)) In particular, Jebine, Kiebine, Okinawan, and the like are suitable as the health supplement of the present invention-In the present invention, the processed product is a dry powder, a small piece, a frozen powder, a pressed product, a pressed product of a corn or ebine. Juices, extracts, extracts, etc. What is processed by such means widely means. It also includes granulation using powder, granules, capsules, and the like. BRIEF DESCRIPTION OF THE FIGURES
第 1図はヒュウガトゥキ加工物及び含有成分によるマウスにおける D — G a 1 N / L P S誘発肝障害抑制作用を示す表であり、 第 2図はヒュ ゥガトウキ含有化合物を用いた第 1世代培養ラッ ト肝細胞における D— G a 1 N誘発肝毒性に関するヒユウガトウキ含有成分の作用を示す表で あり、 第 3図は誘発マウス腹腔内マク口ファージ活性化に対するヒュゥ ガトゥキ含有化合物の一酸化窒素産生抑制活性を示す表であり、 第 4図 はヒュウガトゥキ単独エキス及ぴヒユウガトゥキとェビネの混合エキス の健康補助食品機能を示す表であり、 第 5図は、 ャマニンジンアルコー ル抽出液とィ ソエポキシブテリキシンの C D— 1マウスでの皮膚腫瘍発 生抑制効果を示すグラフで、 （ィ） は腫瘍の発生したマウス数を示し、 (口） はマウス 1匹当たりの腫瘍数を示す。 発明を実施するための最良の形態  Fig. 1 is a table showing the inhibitory effect of the processed product and its components on D-Ga1N / LPS-induced hepatic injury in mice, and Fig. 2 is a first-generation cultured rat liver using a compound containing a hyugatouki. FIG. 3 is a table showing the effect of the components of Hyuuga-touki on D-Ga1N-induced hepatotoxicity in cells. FIG. 3 shows the nitric oxide production inhibitory activity of the compounds containing Hyuga-gatouki on the activation of intraperitoneal macula phage in mice. Fig. 4 is a table showing the health supplement function of Hyugatuki alone extract and a mixed extract of Hyugatuki and Ebine, and Fig. 5 is a chart of Ginseng alcohol extract and Isoepoxybuterixin. A graph showing the inhibitory effect of skin tumor on CD-1 mice. (A) shows the number of mice with tumors, and (mouth) shows the number of tumors per mouse. Show. BEST MODE FOR CARRYING OUT THE INVENTION
本発明に係わる健康補助食品の有効成分であるヒュウガトゥキは、 栽 培種、 野生種の花、 根、 茎、 葉、 枝などを用いる。 通常は、 粉末のごと き固体で用いるが、 抽出液や圧搾汁のごとき液体でも利用できる。 増量 剤、 賦形剤等を添加し、 顆粒、 錠剤、 カプセルなどに成形することもで きる。 摂取を容易にするためには、 甘味剤、 例えばステビアなどを少量 添加することができる。 その他、 健康補助食品に一般的に用いられるビ タミン類などを添加してもよい。  Hyugatuki, which is an active ingredient of the dietary supplement according to the present invention, uses cultivated seeds, wild flowers, roots, stems, leaves, branches, and the like. Usually, it is used as a solid, such as a powder, but it can also be used as a liquid, such as an extract or pressed juice. Additives, excipients, etc. may be added to form granules, tablets, capsules and the like. Sweetening agents, such as stevia, can be added in small amounts to facilitate ingestion. In addition, vitamins commonly used in health supplements may be added.
摂取量は、 通常の健康補助食品として、 粉体にあっては一回に 1 g以 上を、 液体にあっては一回に 2 0 m l以上を、 一日当たり 2〜 3回とる のが望ましい。 As a normal dietary supplement, take 1 g or more at a time for powders, 20 ml or more at a time for liquids, 2-3 times a day. It is desirable.
固体で利用する場合は、 植物を凍結乾燥したり、 風乾したり して粉化 する。 粉化物は、 造粒、 顆粒、 ペレッ ト等に成形してもよい。 粉化せず に植物を細片化して乾燥し、 そのまま用いてもよい。 また、 抽出液ある いは圧搾汁から液体分を溜去して、 粉体を得ることもできる。  When used as a solid, the plant is freeze-dried or air-dried to powder. The powdered product may be formed into granules, granules, pellets and the like. The plant may be fragmented and dried without powdering, and used as it is. Further, a powder can be obtained by distilling a liquid component from the extract or the squeezed juice.
液体で利用する場合は、 通常抽出法または圧搾法による。 抽出法にお いては、 抽出溶媒として水やアルコールなどを用いる。 水とアルコール の混合溶液の使用が一般的で、 その濃度は 1 0〜 1 0 0 %、 好ましくは 4 0〜 8 0 %がよく、 抽出後は植物エキスの効能と取扱の観点から、 ァ ルコール水溶液の濃度を 2 5 %以下に調整するのが望ましい。  When used in liquid form, extraction or squeezing is usually used. In the extraction method, water or alcohol is used as an extraction solvent. It is common to use a mixed solution of water and alcohol, and its concentration is 10 to 100%, preferably 40 to 80% .After extraction, from the viewpoint of the efficacy and handling of the plant extract, alcohol It is desirable to adjust the concentration of the aqueous solution to 25% or less.
圧搾法においては、 地下茎などに付着した泥を落と し、 全草を水洗す る。 次いで、 カッター、 ミキサーなどで粗切して、 プレスにより圧搾す る。 プレスの圧縮圧力は、 5 0 0〜5 , 0 0 0 k g Z c m 2程度に設定 すればよい。 圧搾汁をこのまま、 または精製もしくは希釈して使用する ことができる。 In the squeezing method, the mud adhering to the rhizome is dropped and the whole plant is washed with water. Next, it is roughly cut with a cutter, mixer, etc., and squeezed with a press. Compression pressure of the press is 5 0 0-5 may be set to approximately 0 0 0 kg Z cm 2. The squeezed juice can be used as is, or purified or diluted.
本発明者の実験によれば、 ヒュゥガトウキからは下記のごとき化合物 が単離されており、 そのうちのいくつかについては薬理作用が確認され ている。 解析例 （抽出及び単離）  According to the experiments of the present inventors, the following compounds have been isolated from Hyugatouki, and the pharmacological effects of some of them have been confirmed. Analysis example (extraction and isolation)
宮崎県産ヒュウガトゥキ （A n g e l i c a f u r c i j u g a K i t a g a w a ) の新鮮地下茎 4 , 0 0 0 gを加温下のメタノール約 1 0， 0 0 0 m 1 で抽出後、 減圧下溶媒を留去して、 メタノール抽出ェ キス 2 1 7 . 0 g ( 5 . 4 % ) — (以下カツコ內はいずれも新鮮地下茎か らの収率を示す） を得た。 メタノール抽出エキスのうち、 1 9 5 . 2 g をダイアイオン高速 2 0カラムクロマ トグラフィ一に付し、 H 2 0→M e OH→M e C OM e→M e O Hの順に溶出させ、水溶出部 1 4 0 g ( 3.After extracting 4,000 g of fresh rhizomes of Hyugatuki (Angelicafurcijuga Kitagawa) from Miyazaki with about 100,000 m 1 of methanol under heating, the solvent was distilled off under reduced pressure, and methanol extraction was performed. Kiss 21.7 g (5.4%) — (Katsuko II indicates the yield from fresh rhizomes) was obtained. Of methanol extract, given the 1 9 5. 2 g to Diaion fast 2 0 Karamukuroma Togurafi one, H 2 0 → M e OH → MeC OM e → Me OH in order, eluted with water 140 g (3.
8 9 %) 、 第 1分画分 6. 6 g ( 0. 1 7 %) 、 第 2分画分 1 7. 7 g ( 0. 4 9 %) 、 第 3分画分 2 5. 0 g ( 0. 6 9 %) をそれぞれ得た。 水溶出部及び第 1分画分は、 薄層クロマトグラフィ一の検討から糖類 及びアミノ酸など一次代謝成分であったことから、第 2分画分について、 順相及び逆相シリ力ゲルカラムクロマ トグラフィー、 及び高速液体ク口 マトグラフィー （OD S ) による M e OH— H20、 M e C N— H2O、 2 P r OH— H20で順次溶出した結果、 新規リ ダナン配糖体 t e r e b i n t h a c o s i d e ΙΠ ( 1 1 ) 、 クマリ ン骨格中のラク トン部が 開環した型の新規配糖体 t e r e b i n t h a c o s i d e Π ( 1 0) ( 0. 0 0 2 9 %) 、 新規ァグリコンを有するクマリ ン配糖体 t e r e b i n t h a c o s i d e I ( 6 ) ( 0. 0 0 0 7 9 %) 、 f a l c a r i n d i o 1 ( 0. 0 4 0%) 、 他にクマリン配糖体 a p i o s y 1 s k i mm i n ( 0. 0 3 0 %) 、 h y m e x e 1 s i n ( 0. 0 0 0 9 9 %) 、 p r a e r o s i d e 2 ( 0. 0 1 2 %) 及ぴ 4 ( 0. 0 189%), first fraction 6.6 g (0.17%), second fraction 17.7g (0.49%), third fraction 25.0 g (0.69%), respectively. The water-eluting part and the first fraction were primary metabolites such as saccharides and amino acids based on thin layer chromatography studies.Therefore, the second fraction was subjected to normal-phase and reverse-phase silica gel chromatography. , and high-speed M e OH- H 2 0 by performance liquid inlet Mato chromatography (OD S), M e CN- H 2 O, 2 P r OH- H 2 0 successively eluted result, new re Turan glycoside terebinthacoside 1 (11), terebinthacoside, a new glycoside in which the lactone moiety in the coumarin skeleton is open Π (10) (0.029%), terebinthacoside, a coumarin glycoside having a new aglycone I (6) (0.00.07 9%), falcarindio 1 (0.040%), coumarin glycoside apiosy 1 ski mm in (0.00.30%), hymexe 1 sin ( 0.00 99.9%), praeroside 2 (0.01 2%) and 4 (0.01
9 %) 、 m a r m e s i n i n ( 0. 0 0 0 8 9 %) 、 (R) - p e u c e d a n o 1 7 — 0— /3 — D— g l u c o p y r a n o s i d e ( 0. 0 0 4 4 %) 、 リグナン配糖体 （ + ) — p i n o r e s i n o l 0- /3 -D- g l u c o p y r a n o s i d e ( 0. 0 0 0 1 0 %) を得た。 また第 3分画分について、 順相及び逆相シリカゲルカラムクロマトグ ラフィー、 高速液体クロマトグラフィー （OD S ) による M e OH— H 2O、 M e CN— H2〇、 2 P r OH— H20で順次溶出し、 次いで高速 液体クロマ トグラフィー （ c n) による n— H e x a n e — 2— P r O Hで順次溶出した結果、 三種の-新規ケールラク トン型クマリ ン t e r e b i t h a c i n B ( 1 6 ) ( 0. 0 0 1 9%) 、 t e r e b i n t h a c i n C ( 2 1 ) ( 0. 0 1 4 %) 、 t e r e b i n t h a c i n A ( 1 5 ) (0. 0 1 1 %) 、 i s o e p o x y b u t e r i x i n (0. 04 0 %) 、 a n o m a 1 i n (0. 0 1 3 %) 、 p t e r y x i n (0. 0 1 7%) 、 i s o p t e r y x i n (0. 0 4 0 %) 、 s u k s d r f i n ( 0. 0 1 4 %) 、 s e r a v s c h a n i n (0. 0 0 2 2 %) 、 b e r g a p t e n (0. 0 0 1 1 %) 、 (一) — f a 1 c a r i n o 1 (= p a n a x y n o l ) (0. 0 0 2 1 %) 、 f a 1 c a r i n d i o 1 ( 0. 0 0 4 6 %) 、 3 _ s i t o s t e r o 1 ( 0. 0 3 2 %) が単離された。 試験例 1 (D— G a 1 N/L P S肝障害保護） 9%), marmesinin (0.00.009%), (R) -peucedano 1 7 — 0— / 3 — D— glucopyranoside (0.0004%), lignan glycoside (+) — pinoresinol 0- / 3-D-glucopyranoside (0.0000%) was obtained. The third minute fraction, M e OH- H 2 O by normal phase and reverse phase silica gel column chromatography grayed roughy, high performance liquid chromatography (OD S), M e CN- H 2 〇, 2 P r OH- H 2 Elution at 0 and then elution with n-Hexane-2-PrOH by high performance liquid chromatography (cn). As a result, three types of new kale lactone coumarin terebithacin B (16) (0. 0 0 1 9%), terebinthacin C (2 1) (0.014%), terebinthacin A (15) (0.011%), isoepoxybuterixin (0.004%), anoma 1in (0.013%), pteryxin (0.01.7%), isopteryxin (0.00.0%) 40%), suksdrfin (0.014%), seravschanin (0.0022%), bergapten (0.0011%), (one) — fa 1 carino 1 (= panaxynol) ( 0.021%), fa1 carindio1 (0.046%), and 3_sitostero1 (0.032%) were isolated. Test example 1 (D—Ga 1 N / LPS protection against liver injury)
2 5〜 2 7 gの d d y系雌マウスを用い、 D—ガラク トサミ ン （D— G a 1 N) 3 5 0mg/k g及びリポポリサッカライ ド （L P S) 1 0 μ g/k gを腹腔内注射し、 肝障害を誘発した。 各試験試料は、 D— G a 1 N/L P S注射の 1時間前に与えた。 採血は、 D— G a 1 N/L P S注射の 1 0時間後に行った。 各値は、 S . E . Mによる平均値を示す ( p < 0. 0 5、 p < 0. 0 1 ) 。 各試料の投与量及び血清トランスァ ミラーゼ活性値 （ s— G P T、 s -GOT) を第 1図に示す。 試験例 2 (D— G a 1 N誘発細胞毒性の保護作用）  D-galactosamine (D-Ga1N) 350 mg / kg and lipopolysaccharide (LPS) 10 μg / kg intraperitoneally using 25-27 g ddy female mice Injection induced liver damage. Each test sample was given 1 hour prior to D-GaI N / L PS injection. Blood collection was performed 10 hours after D-Ga1N / L PS injection. Each value indicates the average value by S.E.M (p <0.05, p <0.01). FIG. 1 shows the dose and the serum transaminase activity value (s-GPT, s-GOT) of each sample. Test Example 2 (Protective action against D—Ga1N-induced cytotoxicity)
ヒュウガトゥキ抽出成分の肝保護作用は、 初代培養肝細胞を用いて 3 — (4， 5—ジメチルチアゾル— 2—ィル） — 2—， 5—ジフエニルテ トラゾリ ゥム ブロマイ ド （M T T ) カラーメ トリ ックアツセィにより測 定した。 肝細胞は、 ゥイスター系雄ラッ ト （ 1 3 0〜 1 6 0 g ) からコ ラーゲン散布法により分離した。 仔牛血清 1 0 %、 ペニシリ ン 1 0 0ュ ニッ ト/ m l、 ス ト レプトマイシン 1 0 0 ;z g /m l 、 インシュ リ ン 1 μ Μ, デクサメタゾーン 1 μ Μを含むウイ リアム培養液 1 0 0 μ 1 中に 4X1 04セルからなる細胞懸濁液を 96ゥエル組織培養プレー トに接 種、 5 %C02雰囲気中で 3 7°C、 4時間予備培養した。 培養液を D— G a 1 N ( 1 mM) と試験試料を含む新鮮培養液に変え、 肝細胞を 44 時間培養した。 培養液をさらに 1 00 / 1の培養液に変更、 これに 1 0 ； u 1の MTT溶液 （P B S中 5 m gZm 1 ) を加えた。 4時間培養後培 養液を除去し、 次いで 0. 04 Nの HC 1 を含むイ ソプロパノール 1 0 0 μ 1 を加え、 細胞中に生成されたフオルマザンを溶解した。 フオルマ ザン溶液の光学濃度 （O. D) は、 マイクロプレートリーダーにより、 5 70 n m (リ ファ レンス ： 6 5 5 n m) で測定した。 抑止率は、 次式 数で求めた。 結果を第 2図に示す。 式 The hepatoprotective effect of the extract of Hyugatuki was determined using primary cultured hepatocytes using 3 — (4,5-dimethylthiazol-2-yl) — 2-, 5-diphenyltetrazolazole bromide (MTT) colorimetric assay. It was measured by. Hepatocytes were isolated from male diaster rats (130-160 g) by the collagen spray method. 100% William culture containing 10% calf serum, 100 units of penicillin / ml, 100% streptomycin; zg / ml, 1 μΜ insulin, 1 μΜ dexamethasone During 0 μ 1 4X1 04 cell suspension consisting of cell 96 Ueru tissue culture plates in inoculation, 3 7 ° C, 4 hours were preincubated in 5% C0 2 atmosphere. The culture medium was changed to a fresh culture medium containing D-Ga1N (1 mM) and a test sample, and hepatocytes were cultured for 44 hours. The culture solution was further changed to a culture solution of 100/1, to which was added a 10; u1 MTT solution (5 mgZm1 in PBS). After culturing for 4 hours, the culture solution was removed, and then 100 μl of isopropanol containing 0.04 N of HC 1 was added to dissolve the formazan formed in the cells. The optical density (OD) of the formazan solution was measured at 570 nm (reference: 655 nm) using a microplate reader. The suppression rate was calculated by the following equation. The results are shown in FIG. formula
抑止率 （％) = { (サンプル O. D—対照群 O. D) ÷ (正常群〇. D—対照群 O. D) } 試験例 3 (抗炎症薬理活性）  Inhibition rate (%) = {(Sample OD—Control group OD) ÷ (Normal group 〇. D—Control group OD)} Test example 3 (Anti-inflammatory pharmacological activity)
d d y系雄性マウス （体重約 3 0 g) を頸椎脱臼により安楽死させ、 腹腔内に緩衝生理食塩水 （P B S) を 6〜 7m l注入し、 軽くマッサ一 ジした。得られた腹腔滲出液を P B S、次いで R PM 1 1 640 ( 1 0 % 牛胎仔血清、 1 00ユニッ ト/ m 1ペニシリ ン、 l O O gZm lス ト レブトマイシンを含む） 培地で洗浄した。 96穴平底マイクロプレート に 1 ゥエル当たり 5 X 1 0 5個/ 1 00 μ 1 の細胞を加え、 3 7 °C、 5 % 炭酸ガス一 9 5 %空気下で 1時間培養した。浮遊細胞を P B Sで洗浄し、 上記培養液にリポポリサッカラ-ィ ド （シグマ社製、 サルモネラェンテリ ティディス由来） l O /x g/m l及び被検物質を含むものを 200 μ 1 加え、 2 0時間培養した。 培養上清 1 00 μ 1 にグリース試薬 （ 1 %ス ルファニルァミ ドと 0. 1 %N— 1—ナフチルエチレンジァミ ン ジハイ ドロクロライ ドを 2. 5 %燐酸に溶解したもの） Ι Ο Ο μ Ι を加え、 室 温で 1 0分間放置した。 マイクロプレートリーダ一によつて吸光度を測 定した （測定波長 5 6 2 nm、 対照波長 6 3 0 n m) 。 亜硝酸ナトリ ゥ ムを標準物質として培養液中に蓄積した NO—の量を N Oの生成量とみ なして判定した。 Male ddy mice (body weight about 30 g) were euthanized by cervical dislocation, and 6-7 ml of buffered saline (PBS) was injected into the abdominal cavity and gently massaged. The obtained peritoneal exudate was washed with PBS and then with RPMI 11640 (containing 10% fetal calf serum, 100 units / ml penicillin, 100 gZml and streptomycin) medium. 5 × 10 5 cells / 100 μl of cells were added per well to a 96-well flat bottom microplate, and the cells were cultured at 37 ° C. in a 5% carbon dioxide gas / 95% air atmosphere for 1 hour. The suspended cells are washed with PBS, and 200 μl of lipopolysaccharide (from Sigma, derived from Salmonella enteridisis) containing l O / xg / ml and a test substance is added to the above culture solution, and then added to the culture medium. Cultured for hours. Add 100 g of culture supernatant to a grease reagent (1% (Luphanilamide and 0.1% N-1-naphthylethylenediamine dihydrochloride dissolved in 2.5% phosphoric acid) were added, and the mixture was allowed to stand at room temperature for 10 minutes. The absorbance was measured using a microplate reader (measurement wavelength: 562 nm, control wavelength: 630 nm). The amount of NO— accumulated in the culture broth using sodium nitrite as a standard substance was determined as the amount of NO produced.
被検物質としては、 実施例で取得したフアルカリ ノール、 フアルカリ ンジオール及ぴィソエポキシブテリキシンと、 抗炎症作用が知られてい る対照薬としてハイ ドロコーチゾンを用いた。 結果を第 3図に示す。 第 1図から明らかなように、 対照群では D— G a 1 NZL P S投与の 1 0時間後に著しい肝障害により、 血清トランスアミナーゼ活性 （ s— G PT、 s -GOT) が約 6 0 0 0単位まで上昇したが、 フアルカ リ ン ジオールをはじめ、 ヒュウガトウキ由来物質投与群ではいずれも s— G OT、 s— G Ρ Τの上昇を有意に抑制した。  As test substances, phalkanol, phalkanoldiol, and disoepoxybuterixin obtained in Examples were used, and hydrocortisone was used as a control drug known to have an anti-inflammatory effect. The results are shown in FIG. As is evident from Fig. 1, serum transaminase activity (s-GPT, s-GOT) was about 600 units in the control group due to significant liver damage 10 hours after D-Ga1 NZL PS administration. However, s-GOT and s-G Ρ 上昇 were significantly suppressed in the groups administered with the substances derived from Hyuga-touki, including pharmacaldiol.
この実験モデルにおいては、 D— G a I Nでやや障害を受けた肝細胞 に L P S刺激で活性化したマク ロファージが作用することによって強い 障害が発生すると考えられている。 そこで、作用機序を解明する目的で、 初代培養肝細胞を用い、 D— G a 1 Nによる細胞毒性からの保護作用に ついて MTTアツセィ法により検討した。 MTTァッセィ法は細胞の脱 水素酵素によって黄色の MTTが赤紫色のホルマザンに変化することを 利用した細胞数測定方法である。 その結果、 第 2図に示すように、 イソ エポキシブテリキシンには濃度依存的な肝細胞保護作用が認められた。 一方、 ファルカリ ンジオールにほ、逆に肝細胞に対する毒性がみられた。 その他の微量成分としてィ ソプテリキシン （ i s o p t e r y x i n) に保護作用が認められた。 また、 L P Sによるマク口ファージの活性化にともなつて産生される —酸化窒素 （NO) の量を指標に、 マクロファージの活性化を抑制する かどうか検討した。 NOはただちに酸化され NO 2 に変化するため、 培 養液中の NO2 の量を N〇の量とみなした。 イソエポキシブテリキシン およびフアルカリンジオールは、 第 3図に示すようにマクロファージに 対して細胞毒性を示さない濃度で NOの産生を強く抑制した。 In this experimental model, it is thought that strong damage is caused by the action of macrophages activated by LPS stimulation on hepatocytes slightly damaged by D-GaIN. Therefore, for the purpose of elucidating the mechanism of action, primary protective hepatocytes were used to examine the protective effect against cytotoxicity of D-Ga1N by the MTT assay. The MTT assay method is a cell counting method that utilizes the fact that yellow MTT changes to magenta formazan by cell dehydrogenase. As a result, as shown in FIG. 2, iso-epoxybuterixin exhibited a concentration-dependent hepatocyte protective effect. On the other hand, falcarindiol, on the contrary, showed toxicity to hepatocytes. Isopteryxin was found to have a protective effect as another minor component. In addition, we examined whether macrophage activation was suppressed by using the amount of nitric oxide (NO), which is produced by the activation of macula phage by LPS. Since NO is that changes to NO 2 immediately oxidized, it was considered as the amount of N_〇 the amount of NO 2 in the culture solution. As shown in FIG. 3, isoepoxybuterixin and phalkariandiol strongly inhibited NO production at a concentration that was not cytotoxic to macrophages.
ァノマリン （ a n o m a 1 i n) 、 ベノレガプテン （b e r g a p t e n ) 、 セラブシャニン （ s e r a v s c h a n i n) 、 イソプテリキシ ンゃ新規化合物テレビンタシン Aにも抑制作用が認められ、 特に、 ファ ルカリンジオールに強い活性が認められた。 フアルカリンジォ一ルは肝 細胞毒性を示すにもかかわらず、 マクロファージの活性化を強く抑制す るため、 この肝障害を抑制したものと考えられる。 また、 イソエポキシ ブテリキシンは肝臓側に作用して肝保護作用を示すのみならず、 マクロ ファージの活性化を抑制することによって D— G a 1 N/ I P Sによる 肝障害を抑制するものと推察される。 試験例 4 (抗腫瘍薬理活性）  Anomalin (anoma1 inn), benoregapten (bergapten), cellabshanin (servashchanin), and isopterixin, a novel compound, telentacin A, also exhibited an inhibitory effect, and particularly strong activity of falcarindiol was observed. Despite showing hepatocellular toxicity, pharmacandiol strongly suppresses the activation of macrophages, and is considered to have suppressed this liver injury. In addition, isoepoxybuterixin not only exerts hepatoprotective action by acting on the liver side, but also suppresses D-Ga1N / IPS-induced liver damage by suppressing macrophage activation. . Test Example 4 (Anti-tumor pharmacological activity)
実験動物に雌の CD— 1系？〜 8週令のマウスを一群 2 0匹とした。 実験 2 日前、 バリカンで剃毛して、 毛の成育休毛期のマウスを用いた。 試料はすべてアセ トンに溶解させ、 マイクロピペッ トで 0. 2 m l剃毛 した皮膚に塗布した。 まず発癌のイニシエータ一と してジメチルベンゼ ンアントラセン （DMBA) 2 0 0 n m 0 1 をマウス皮膚に塗布した。 1 0 日後に週 2回テ トラデカノールホルボール— 1 3—ァセテート （T PA) 5 n m o 1 を塗布し、 1 8週間続けた。 試料は、 T P A塗布と同 時に週 2回塗布、 1 8週間続けた。 判定は腫瘍のマウス当たりの数とマ ウスに腫瘍の発生した割合との 2種で評価した。 結果を第 5図に示す。 第 5図から明らかなように、 ヒュウガトゥキエキス群及びィソェポキ シブテリキシン群には、 明白な抗腫瘍効果が認められた。抗腫瘍効果は、 腫瘍の発生したマウスの数でも、 マウス 1匹当たりの腫瘍数においても 確認された。 Female CD-1 in experimental animals? Groups of 88-week-old mice were grouped into 20 mice. Two days before the experiment, mice with shaved hair and a hair resting period were used. All samples were dissolved in acetone and applied with 0.2 ml of micropipette to shaved skin. First, dimethylbenzenanthracene (DMBA) 200 nm 01 was applied to mouse skin as an initiator of carcinogenesis. Ten days later, 5 nmol of tetradecanol phorbol-13-acetate (TPA) was applied twice a week, and the treatment was continued for 18 weeks. The samples were applied twice a week at the same time as the TPA application and continued for 18 weeks. Judgment was made on two types, the number of tumors per mouse and the rate of occurrence of tumors in mice. The results are shown in FIG. As is clear from FIG. 5, the anti-tumor effect was clearly observed in the hyugatuki extract group and the isosepoxybuterixin group. The antitumor effect was confirmed both in the number of mice with tumors and in the number of tumors per mouse.
一方、 セリ科シシウ ド属に属する植物の加工物とラン科ェビネ属に属 する植物の加工物との混合物を有効成分とする健康補助食品では、 トゥ キ類の加工物とェビネ類の加工物の組成割合を、 トゥキ類及びェビネ類 の圧搾汁及び Zまたは抽出液の場合は、 トウキ類の 6〜 8に対して、 ェ ビネ類の 4〜 2が望ましい。 ェビネ類の混合割合が多いと、 刺激性が強 く摂取が困難となる。 また食酢、 特に黒酢を添加すると健康補助食品機 能を著しく増進する。 食酢の添加により混合液の p Hを 3〜 5程度に調 整するのが、 保存性向上の意味から望ましい。 さらに摂取を容易にする ため甘味剤、 例えばステビアなどを少量添加するとよい。 その他、 健康 補助食品に一般的に用いられるビタミン類などの添加は任意である。  On the other hand, health supplements containing as an active ingredient a mixture of a processed product of a plant belonging to the genus Umbelliferae and a processed product of a plant belonging to the genus Ebine belong to the processed products of the ibis and ebine. In the case of the squeezed juice and Z or the extract of eucalyptus and ebine, the composition ratio of ebine is preferably 4 to 2 with respect to 6 to 8 of eucalyptus. If the mixing ratio of ebine is high, it is highly irritating and difficult to ingest. The addition of vinegar, especially black vinegar, significantly enhances the function of dietary supplements. It is desirable to adjust the pH of the mixed solution to about 3 to 5 by adding vinegar from the viewpoint of improving storage stability. In addition, sweeteners such as stevia may be added in small amounts to facilitate ingestion. In addition, the addition of vitamins commonly used in health supplements is optional.
このトウキ類とェビネ類の混合系健康補助食品は、 通常は圧搾汁また は抽出液からなる液体飲料と して提供されるが、 トゥキ類及びェビネ類 を粉化してそのまま混合して粉体、 顆粒、 錠剤、 カプセルで提供するこ ともできる。 また圧搾汁や抽出液に増量剤、 賦形剤等を添加し、 顆粒、 錠剤、 カプセルなどに成形することもできる。  This mixed dietary supplement of eucalyptus and ebine is usually provided as a liquid beverage consisting of squeezed juice or extract. They can also be provided in granules, tablets, and capsules. Additives, excipients, etc. can be added to the squeezed juice or extract to form granules, tablets, capsules and the like.
一日あたりの摂取量は、 通常の液体健康補助食品として、 1 0〜 3 0 m l Z回を 2回〜 3回とればよい。  The daily intake should be 10 to 30 ml Z 2 to 3 times as a normal liquid health supplement.
本発明の健康補助食品は、 例えば次のように製造できる。 まず原料と なる トウキ類及びェビネ類は、 いずれも葉、 茎、 花、 根等の全草を使用 することができるが、 特に根が望ましい。 両者とも全草を水洗し、 カツ ター、 ミキサーなどで粗切りする。 次いで、 粗切り して乾燥した トウキ 類 2 k gを水 2 0 リ ツ トルの割合で炊く。 一方ェビネ類 1 k gは水 1 0 リッ トルの割合で炊く。 圧搾汁でもよいが、 最終的には容量が約 1 / 3 程度になるまでとろ火で炊きしめる。 通常、 4〜 5時間を要する。 煮沸 後常温まで放冷し、 濾過過、 混合する。 混合液には、 望ましくは黒酢を 5〜 1 5 %加え、 p H 3〜 5程度に調整する。 これに甘味剤として例え ばステビアを適量入れ、 飲みやすくする。 The health supplement of the present invention can be produced, for example, as follows. First of all, as the raw materials, all vegetation such as leaves, stems, flowers, and roots can be used for the ibis and ebine, but the root is particularly preferable. In both cases, the whole plant is washed with water, and cut with a cutter or mixer. Next, 2 kg of the roughly cut and dried oysters are cooked at a rate of 20 liters of water. On the other hand, 1 kg of ebine is water 10 Cook at a little rate. Pressed juice may be used, but cook over low heat until the volume is reduced to about 1/3. Usually takes 4-5 hours. After boiling, allow to cool to room temperature, filter and mix. The mixture is desirably added with 5 to 15% of black vinegar to adjust the pH to about 3 to 5. Add an appropriate amount of sweetener, such as stevia, to make it easier to drink.
得られた混合組成物では、 トウキ類の強力な抗癌作用、 抗肝炎作用な どに加えて、 ェビネ類の強い抗菌、 抗炎症作用が働き、 これまでにない 広い範囲での疾病改善作用、 健康保持機能が達成される。 モニター調査 によれば、 トウキ類とェビネ類の複合的な作用により、 単独使用に比べ て抗癌作用、 B型及び C型の抗肝炎作用、 抗糖尿病作用が著しく増進す る。 特に抗癌作用においては、 トウキ類だけでは一旦改善に向かうが再 発しがちである。 しかし、 ェビネ類を混合すると、 この再発率が著しく 抑制される。 実施例 1  In the resulting mixed composition, in addition to the potent anticancer action and anti-hepatitis action of rubrum, the strong antibacterial and anti-inflammatory action of ebine works, and it has an unprecedented wide range of disease ameliorating action. Health maintenance function is achieved. According to monitoring studies, the combined effects of ibis and ebine significantly enhance the anticancer, anti-hepatitis B and C, and anti-diabetic effects compared to single use. In particular, with respect to anticancer effects, rubbing alone tends to improve once but tends to recur. However, the mixing of ebine significantly reduces this recurrence rate. Example 1
宮崎県南部に自生するヒュウガトゥキを用いた。 葉、 茎、 根等の全草 を水洗し、 力ッターで粗切り した。 粗切り した乾燥ヒユウガトゥキ 2 k gを水 2 0 リ ツ トルで煮沸した。 最終的には容量が約 1 / 3程度になる までとろ火で炊きしめた。 煮沸時間は 4時間であった。 煮沸後常温まで 放冷し、 固形物を濾別した。 混合液には黒酢を全量の約 1 0 %加え、 p Hが 4になるように調整した。 これに甘味剤として、 ステビアを少量入 れた。 実施例 2 ―  Hyugatuki native to southern Miyazaki prefecture was used. The leaves, stems, roots, and other whole plants were washed with water and roughly cut with a power cutter. 2 kg of the dried and dried hyuugatsuki was boiled with 20 liters of water. Finally, they cooked on low heat until the capacity was about 1/3. The boiling time was 4 hours. After boiling, the mixture was allowed to cool to room temperature, and the solid was filtered off. About 10% of the total amount of black vinegar was added to the mixture, and the pH was adjusted to 4. A small amount of stevia was added to this as a sweetener. Example 2 ―
トウキ類には、 宮崎県南部に自生するヒュウガトゥキを用い、 同様に ェビネ類には宮崎県南部に自生するジェビネを用いた。 いずれも葉、茎、 根等の全草を水洗し、 力ッターで粗切り した。 粗切り した乾燥ヒュウガ トウキ 2 k gを水 2 0 リ ツ トルで煮沸した。 粗切り したジェビネ 1 k g は水 1 0 リ ッ トルで煮沸した。 最終的には容量が約 1 3程度になるま でとろ火で炊きしめた。 煮沸時間は 4時間であった。 煮沸後常温まで放 冷し固形物を濾別した後、 混合した。 混合液には黒酢を全量の約 1 0 % 加え、 p Hが 4になるように調整した。 これに甘味剤と して、 ステビア を少量入れた。 対照例 1 Hyugatuki native to southern Miyazaki prefecture was used for corn, and Jebine native to southern Miyazaki prefecture was used for ebine. All leaves, stems, The whole plant, including the roots, was washed with water and roughly cut with a power cutter. 2 kg of the dried and dried hyuga touki was boiled with 20 liters of water. 1 kg of the coarsely cut Jebine was boiled with 10 liters of water. Finally, they cooked on low heat until the capacity reached about 13. The boiling time was 4 hours. After boiling, the mixture was allowed to cool to room temperature, and solids were separated by filtration and mixed. About 10% of the total amount of black vinegar was added to the mixture, and the pH was adjusted to 4. A small amount of stevia was added to this as a sweetener. Control Example 1
原料と して、 宮崎県に自生するジェビネの全草のみを用いた以外は実 施例 1 と同じ方法で製造した。 対照例 2  Manufacture was carried out in the same manner as in Example 1, except that only the whole plant of Jebine native to Miyazaki Prefecture was used as a raw material. Control 2
黒酢と甘味剤のみからなる以外は、 実施例 1 と同じ方法で製造した。 前記実施例 1、 2及び対照例 1、 2に示す試料の疾病改善機能及び健 康保持機能を定性的に第 4図に示す。 抗癌作用例 ： トウキ類の抗癌作用は、 トウキ類に含まれるイソェポキ シブテリ キシン、 新規クマリ ンのテレビンタコサイ ド A、 テレビンタコ サイ K B、 新規クマリン配糖体のテレビンタコサイ ド I 、 クマリ ン骨格 中のラク トンが開環した新規化合物のテレビンタコサイ ド Π、 新規リグ ナンテレビンタコサイ ド mに認められる。 また、 古くから子宮疾患特効 薬として知られているェビネ類にも、 抗癌作用が認められている。  Except for consisting only of black vinegar and a sweetener, it was produced in the same manner as in Example 1. FIG. 4 qualitatively shows the disease improving function and the health maintenance function of the samples shown in Examples 1 and 2 and Control Examples 1 and 2. Examples of anticancer effects: The anticancer effects of corns include isepoxyshibuterixin, which is a new coumarin, terantacoside A, a turpentine KB, a new coumarin glycoside, turpentine I, The lactone in the coumarin skeleton is found in the ring-opened new compound telternacide Π and the new lignan tetancoside m. In addition, anti-cancer effects have also been recognized on ebine, which has long been known as a specific drug for uterine diseases.
抗肝炎作用例 ： トウキ類エキスとしての抗肝炎作用は、 特開平 4一 3 3 6 5号公報で知られているが、 本発明者の知見によれば、 トウキ類に 含まれるファルカリンジオール、 ィソエポキシブテリキシンでも認めら れる。 Example of anti-hepatitis action: The anti-hepatitis action as a citrus extract is known in Japanese Patent Application Laid-Open No. Hei 4-33665. It is also found in the contained falcarin diol and isoepoxybuterixin.
抗炎症作用例 ： トウキ類エキスとしての抗炎症作用は、 特公平 5— 4 8 2 3 3号でも知られているが、 本発明者の知見によれば、 トウキ類に 含まれるフアルカリ ノ一ル、 フアルカリンジオールでも認められる。 抗ァレルギ一作用例 ： トゥキ類含有ィソエポキシブテリキシンには、 抗炎症、 抗ァレルギ一活性があることが特公平 5— 4 8 2 3 3号で知ら れている。 また本発明者の知見によれば、 ェビネ類に含まれるインジル ビンやトリプタ ト リンなどには、 強い抗ァレルギ一作用があり、 抗ァ ト ピ一、 抗フケ剤、 抗菌剤等としての作用も認められる。  Example of anti-inflammatory action: The anti-inflammatory action as a rubrum extract is also known in Japanese Patent Publication No. 5-48233, but according to the knowledge of the present inventors, it is known that the alkanol contained in rubbles contains , And also found in phthalic diols. Example of anti-allergic action: It is known in Japanese Patent Publication No. 5-482333 that iso-epoxybuterixin containing turkeys has anti-inflammatory and anti-allergic activity. Further, according to the findings of the present inventors, indirubin and tryptatrin contained in ebine have a strong antiallergic action, and also have an action as an antitopy, an antidandruff agent, an antibacterial agent and the like. Is recognized.
抗糖尿病作用例 ： トウキ類エキスとしての抗糖尿病作用は特開平 7— 5 3 5 6 0号でも知られているが、 本発明者の知見によればトウキ類に 含まれるファルカリンジオールでも認められる。  Example of anti-diabetic action: The anti-diabetic action as a eucalyptus extract is also known in Japanese Patent Application Laid-Open No. 7-530600, but according to the knowledge of the present inventors, it is also recognized in falcarindiol contained in eucalyptus. .
血管拡張作用例 ： トウキ類エキスとしての血管拡張作用は、 特開平 4 — 3 3 6 5号公報、 トウキ類に含まれるイソエポキシブテリキシンとし ては特開平 7 - 5 3 5 6 0号公報で知られているが、 本発明者の知見に よればェビネ類にも強い血管拡張作用が認められる。  Example of vasodilatory action: The vasodilatory action as an extract of eucalyptus is disclosed in Japanese Patent Application Laid-Open No. 4-33665, and the isoepoxybuterixin contained in eucalyptus is disclosed in Japanese Patent Application Laid-open No. Hei 7-53560. However, according to the findings of the present inventors, strong vasodilatory action is also observed for Ebine.
抗高脂血症作用例 ： トゥキ類エキスとしての抗脂血症作用は特公平 4 - 3 3 6 5号公報で知られている。 産業の利用可能性  Example of anti-hyperlipidemic action: The anti-lipidemic action as a turkey extract is known from Japanese Patent Publication No. 4-33365. Industrial availability
本発明のヒュウガトゥキは、 多数の薬理活性物質を含み、 例えば抗癌 作用、 抗肝炎作用を抑制するも健康補助食品として広く利用できる。 ま た、 ヒュウガトゥキは、 天然植物で副作用もなく、 安心して長期にわた り服用できる。  The hyugatuki of the present invention contains a large number of pharmacologically active substances and, for example, suppresses an anticancer effect and an antihepatitis effect and can be widely used as a health supplement. In addition, hyugatuki is a natural plant with no side effects and can be taken for a long time with confidence.
また、 本発明のトウキ類とェビネ類の圧搾汁、 抽出液からなる混合物 は、 各々の単独組成物に比べて、 広い範囲で各種疾病改善効果を有する とともに、 強力な健康維持機能を有し、 健康補助食品と して、 例えば抗 癌、 肝炎治療、 抗炎症、 抗アレルギー疾患、 糖尿病、 血管拡張、 高脂血 症治療、 動脈硬化予防、 強精等の多様な用途が期待できる。 特に再発率 の少ない抗癌、 抗肝炎作用を有する健康補助食品として有効である。 ま たトウキ類もェビネ類もともに天然に自生する植物で、急性毒性も.なく、 安全に長期間服用できるので、 慢性疾患や生活習慣病の改善等、 日常の 健康維持に好適である。 Also, a mixture comprising a squeezed juice and an extract of the corns and ebine of the present invention Has a wide range of illness-improving effects and a strong health-maintaining function as compared with the individual compositions, and as a health supplement, for example, anti-cancer, hepatitis treatment, anti-inflammatory, anti-allergy It can be expected to have various uses such as diseases, diabetes, vasodilation, treatment of hyperlipidemia, prevention of arteriosclerosis, and stamina. It is especially effective as a health supplement with anti-cancer and anti-hepatitis effects with a low recurrence rate. In addition, both ibis and ebine are naturally occurring plants, have no acute toxicity and can be taken safely for a long period of time. Therefore, they are suitable for daily health maintenance such as improvement of chronic diseases and lifestyle-related diseases.

Claims

請 求 の 範 囲 The scope of the claims
1 . セリ科シシゥ ド属ヒュゥガトウキの加工物を有効成分とすることを 特徴とする健康補助食品。 1. A dietary supplement comprising a processed product of the genus Apiaceae genus Hyugatouki as an active ingredient.
2 . さらに、 ラン科ェビネ属に属する植物の加工物を有効成分と して含 むことを特徴とする請求項 1記载の健康補助食品。 2. The dietary supplement according to claim 1, further comprising a processed product of a plant belonging to the genus Ebine as the active ingredient.
3 . セリ科シシウ ド属に属する植物の加工物と、 ラン科ェビネ属に属す る植物の加工物とを有効成分とすることを特徴とする健康補助食品。 3. A dietary supplement characterized by comprising, as active ingredients, a processed product of a plant belonging to the genus Ceratophyta and a processed product of a plant belonging to the genus Ebine.
4 . セリ科シシゥ ド属に属する植物が、 トウキ、 ィヌ トゥキ及びヒュゥ ガトウキからなる群から選ばれた少なく ともひとつであることを特徴と する請求項 3記載の健康補助食品。 4. The dietary supplement according to claim 3, wherein the plant belonging to the genus Sisidaceae belongs to at least one member selected from the group consisting of Touki, Inutuki and Hyugatouki.
5 . ラン科ェビネ属に属する植物が、 ジェビネ、 キエビネ及びォキナヮ ェビネからなる群から選ばれた少なく ともひとつであることを特徴とす る請求項 3記載の健康補助食品。 5. The dietary supplement according to claim 3, wherein the plant belonging to the genus Ebine belongs to at least one selected from the group consisting of Jebine, Kiebine and Okinawan.
6 . セリ科シシゥ ド属に属する植物及びラン科ェビネ属に属する植物の 加工物が圧搾汁及び/または抽出液であって、 セリ科シシゥ ド属に属す る植物の圧搾汁及び/または抽出液 6〜 8に対して、 ラン科ェビネ属に 属する植物の圧搾汁及び/または抽出液が 4〜 2の割合で混合されてい ることを特徴とする請求項 3記載の健康補助食品。 6. The processed product of a plant belonging to the genus Apiaceae and the plant belonging to the genus Ebine of the orchid family is a squeezed juice and / or an extract, and a squeezed juice and / or an extract of a plant belonging to the genus Aceraceae. 4. The health supplement according to claim 3, wherein a squeezed juice and / or an extract of a plant belonging to the genus Ebine belongs to the ratio of 6 to 8 in a ratio of 4 to 2.
7 . さらに食酢を含み、 p Hが 3〜 5に調整されていることを特徴とす る請求項 6記載の健康補助食品。 7. It contains vinegar and its pH is adjusted to 3 ~ 5. The dietary supplement according to claim 6, wherein
PCT/JP1999/006238 1998-11-11 1999-11-10 Health-promoting foods WO2000027224A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU11765/00A AU1176500A (en) 1998-11-11 1999-11-10 Health-promoting foods

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP31971298 1998-11-11
JP10/319712 1998-11-11

Publications (1)

Publication Number Publication Date
WO2000027224A1 true WO2000027224A1 (en) 2000-05-18

Family

ID=18113344

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP1999/006238 WO2000027224A1 (en) 1998-11-11 1999-11-10 Health-promoting foods

Country Status (2)

Country Link
AU (1) AU1176500A (en)
WO (1) WO2000027224A1 (en)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6872409B2 (en) * 2001-10-17 2005-03-29 Braingenesis Biotechnology Co., Ltd. Composition of traditional chinese medicines for preventing and treating cerebrovascular disease
JP2006515314A (en) * 2003-04-22 2006-05-25 ラボラトリオ キミコ インターナショナール ソシエタ ペル アチオネ Basic salt of thioctic acid with L-carnitine
JP2008125454A (en) * 2006-11-22 2008-06-05 Manabu Nomura Dietary supplement and method for producing the same
WO2012004875A1 (en) * 2010-07-08 2012-01-12 株式会社河野メリクロン Novel substance separated from orchidaceous plant, and extract, antioxidant, antibacterial agent, anticancer agent and antiinflammatory agent containing same
JP2012102068A (en) * 2010-11-13 2012-05-31 Showa Univ Melanism promoter for skin and hair, and external medicine for melanism promotion and food or drink product for melanism promotion including the melanism promoter
JP2015003874A (en) * 2013-06-20 2015-01-08 株式会社エレガントジャパン Cyclooxygenase activity inhibitor and composition containing cyclooxygenase activity inhibitor
CN104352796A (en) * 2014-12-03 2015-02-18 张福国 Pharmaceutical composition for treating orthodontic gingivitis
JP2015038117A (en) * 2014-10-06 2015-02-26 学校法人昭和大学 Melanism promoter of skin and hair, external preparation for melanism promotion containing melanism promoter thereof and food and drink for melanism promotion
JP6095823B1 (en) * 2016-03-24 2017-03-15 株式会社かめいあんじゅ Seasoning liquid for pickles, pickles using the same, and pickles in containers

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH043365B2 (en) * 1984-06-07 1992-01-23
JPH0548233B2 (en) * 1986-12-12 1993-07-20 Nippon Yamaninjin Kenkyusho Kk
JPH10139676A (en) * 1996-11-07 1998-05-26 Manabu Nomura Antiallergic composition for skin lotion

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH043365B2 (en) * 1984-06-07 1992-01-23
JPH0548233B2 (en) * 1986-12-12 1993-07-20 Nippon Yamaninjin Kenkyusho Kk
JPH10139676A (en) * 1996-11-07 1998-05-26 Manabu Nomura Antiallergic composition for skin lotion

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6872409B2 (en) * 2001-10-17 2005-03-29 Braingenesis Biotechnology Co., Ltd. Composition of traditional chinese medicines for preventing and treating cerebrovascular disease
JP2006515314A (en) * 2003-04-22 2006-05-25 ラボラトリオ キミコ インターナショナール ソシエタ ペル アチオネ Basic salt of thioctic acid with L-carnitine
JP4688502B2 (en) * 2003-04-22 2011-05-25 ラボラトリオ キミコ インターナショナール ソシエタ ペル アチオネ Basic salt of thioctic acid with L-carnitine
JP2008125454A (en) * 2006-11-22 2008-06-05 Manabu Nomura Dietary supplement and method for producing the same
WO2012004875A1 (en) * 2010-07-08 2012-01-12 株式会社河野メリクロン Novel substance separated from orchidaceous plant, and extract, antioxidant, antibacterial agent, anticancer agent and antiinflammatory agent containing same
JP2012102068A (en) * 2010-11-13 2012-05-31 Showa Univ Melanism promoter for skin and hair, and external medicine for melanism promotion and food or drink product for melanism promotion including the melanism promoter
JP2015003874A (en) * 2013-06-20 2015-01-08 株式会社エレガントジャパン Cyclooxygenase activity inhibitor and composition containing cyclooxygenase activity inhibitor
JP2015038117A (en) * 2014-10-06 2015-02-26 学校法人昭和大学 Melanism promoter of skin and hair, external preparation for melanism promotion containing melanism promoter thereof and food and drink for melanism promotion
CN104352796A (en) * 2014-12-03 2015-02-18 张福国 Pharmaceutical composition for treating orthodontic gingivitis
JP6095823B1 (en) * 2016-03-24 2017-03-15 株式会社かめいあんじゅ Seasoning liquid for pickles, pickles using the same, and pickles in containers
JP2017169490A (en) * 2016-03-24 2017-09-28 株式会社かめいあんじゅ Seasoning liquid for pickle, pickle using the same, and packed pickle

Also Published As

Publication number Publication date
AU1176500A (en) 2000-05-29

Similar Documents

Publication Publication Date Title
Lin et al. Cordyceps as an herbal drug
WO1997033593A1 (en) A product of heat treatment of uronic acid, food, drink or drug including the product
JP2003192605A (en) Lipase inhibitant
KR20030041813A (en) Reduction inhibitory agent for active oxygen eliminating activity
WO2000027224A1 (en) Health-promoting foods
KR20140017932A (en) Composition of diabetes-improving effective constituents by fermentation products of the trifoliate orange
KR101611853B1 (en) Aster glehni fractions or compounds isolated therefrom having anti-inflammatory activity
JPWO2002062365A1 (en) Method for producing phenol-containing Labiatae plant extract and its use
CN110679824A (en) Fresh noodle preservative and preparation method thereof
KR101902932B1 (en) A composition for preventing, improving or treating alcoholic gastritis of the extracts from the aerial parts except flower and root of Cirsium japonicum and Taraxacum coreanum
KR101491493B1 (en) Anti-inflammatory pharmaceutical composition comprising tangerine pericarp and Psidium guajava extract
KR102368892B1 (en) A composition for anti-inflammatory comprising extracts of single leaf cremastra and sigesbeckia glabrescens makino
KR101207239B1 (en) A composition for the prevention and treatment of inflammatory disease comprising the fractions of Asparagus cochinchinensis as an active ingredient
KR102248059B1 (en) Composition for anti-inflammatory or whitening comprising green barley extract or its fractions and uses thereof
KR101636608B1 (en) Composition for antioxidation comprising the seed extract of cornus officinalis
KR101769774B1 (en) Health functional food for preventing or treatment tumor
KR101514284B1 (en) The pharmaceutical composition for prevention or treatment of cancer comprising an extract of Oplopanax elatus
KR100590726B1 (en) Composition comprising extract of Phellinus sp. PL3 or Phellinsin A isolated from the same as an effective component for prevention and treatment of cardiac circuit disease
KR20150072659A (en) Hepatoprotective composition containing smilax china extract
KR102496752B1 (en) Fruits of Acanthopanax Sessiliflorus extract including alcoholic liver injury prevention functional ingredients and method for manufacturing it
KR20120031706A (en) Preparation method of codonopsis lanceolata extracts using ultra-high pressure
KR102483814B1 (en) Compositions for Anti-Bacterial and Anti-Inflammatory Effect Comprising Oil of Ulvoid green algae
KR102093817B1 (en) Polysaccharide fraction isolated from Nelumbo nucifera leaf with immune-enhancing activity and method for producing the same
KR102281794B1 (en) Composition for protecting hepatic damage on heavy metal comprising extracts from Dendropanax morbifera
KR20130058388A (en) Antioxidative composition comprising fermented liriope platyphylla extract as an active ingredient

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref country code: AU

Ref document number: 2000 11765

Kind code of ref document: A

Format of ref document f/p: F

AK Designated states

Kind code of ref document: A1

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642